These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 30987058)

  • 1. Nutraceuticals for the Treatment of Diabetic Retinopathy.
    Rossino MG; Casini G
    Nutrients; 2019 Apr; 11(4):. PubMed ID: 30987058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic Retinopathy: Pathophysiology and Treatments.
    Wang W; Lo ACY
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29925789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 Inhibitor-Induced Low-Grade Ketonemia Ameliorates Retinal Hypoxia in Diabetic Retinopathy-A Novel Hypothesis.
    Mudaliar S; Hupfeld C; Chao DL
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1235-1244. PubMed ID: 33512450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pigment epithelium-derived factor inhibits retinal microvascular dysfunction induced by 12/15-lipoxygenase-derived eicosanoids.
    Ibrahim AS; Tawfik AM; Hussein KA; Elshafey S; Markand S; Rizk N; Duh EJ; Smith SB; Al-Shabrawey M
    Biochim Biophys Acta; 2015 Mar; 1851(3):290-8. PubMed ID: 25562624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of streptozotocin-induced diabetic retinopathy with low molecular weight fucoidan via inhibition of vascular endothelial growth factor.
    Yang W; Yu X; Zhang Q; Lu Q; Wang J; Cui W; Zheng Y; Wang X; Luo D
    Exp Eye Res; 2013 Oct; 115():96-105. PubMed ID: 23810809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of leukotrienes in diabetic retinopathy.
    Behl T; Kaur I; Kotwani A
    Prostaglandins Other Lipid Mediat; 2016 Jan; 122():1-9. PubMed ID: 26673555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nutraceuticals for Diabetic Retinopathy: Recent Advances and Novel Delivery Systems.
    Ye X; Fung NSK; Lam WC; Lo ACY
    Nutrients; 2024 May; 16(11):. PubMed ID: 38892648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMGB1 siRNA can reduce damage to retinal cells induced by high glucose in vitro and in vivo.
    Jiang S; Chen X
    Drug Des Devel Ther; 2017; 11():783-795. PubMed ID: 28352154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of microglia in the retina: new insights into diabetic retinopathy.
    Arroba AI; Valverde ÁM
    Acta Diabetol; 2017 Jun; 54(6):527-533. PubMed ID: 28349217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy.
    Deliyanti D; Lee JY; Petratos S; Meyer CJ; Ward KW; Wilkinson-Berka JL; de Haan JB
    Clin Sci (Lond); 2016 Aug; 130(15):1375-87. PubMed ID: 27005782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection as a Therapeutic Target for Diabetic Retinopathy.
    Hernández C; Dal Monte M; Simó R; Casini G
    J Diabetes Res; 2016; 2016():9508541. PubMed ID: 27123463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of diabetic retinopathy through neuropeptide Y-mediated enhancement of neurovascular microenvironment.
    Ou K; Copland DA; Theodoropoulou S; Mertsch S; Li Y; Liu J; Schrader S; Liu L; Dick AD
    J Cell Mol Med; 2020 Apr; 24(7):3958-3970. PubMed ID: 32141716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current trends in the pharmacotherapy of diabetic retinopathy.
    Kumar B; Gupta SK; Saxena R; Srivastava S
    J Postgrad Med; 2012; 58(2):132-9. PubMed ID: 22718058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novelties in Diabetic Retinopathy.
    Ebneter A; Zinkernagel MS
    Endocr Dev; 2016; 31():84-96. PubMed ID: 26824524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
    Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
    Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor Therapy.
    Gross JG; Glassman AR
    JAMA Ophthalmol; 2016 Jan; 134(1):13-4. PubMed ID: 26583372
    [No Abstract]   [Full Text] [Related]  

  • 17. Treating diabetic retinopathy by inhibiting growth factor pathways.
    Frank RN
    Curr Opin Investig Drugs; 2009 Apr; 10(4):327-35. PubMed ID: 19337953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niaspan inhibits diabetic retinopathy‑induced vascular inflammation by downregulating the tumor necrosis factor‑α pathway.
    Wang Y; Meng X; Yan H
    Mol Med Rep; 2017 Mar; 15(3):1263-1271. PubMed ID: 28138697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Oxidative Stress in Diabetic Retinopathy and the Beneficial Effects of Flavonoids.
    Ola MS; Al-Dosari D; Alhomida AS
    Curr Pharm Des; 2018; 24(19):2180-2187. PubMed ID: 29766782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Benefits of Flavonoids in Diabetic Retinopathy.
    Matos AL; Bruno DF; Ambrósio AF; Santos PF
    Nutrients; 2020 Oct; 12(10):. PubMed ID: 33081260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.